Main Article Content
Many bacterial pathogens are exhibiting resistance to increasing numbers of antibiotics making it much more challenging to treat the infections caused by these microbes. In many reports in the media and perhaps even in discussions among physicians and biomedical scientists, these bacteria are frequently referred to as “bugs” with the prefix “super” appended. This terminology has a high potential to elicit unjustified inferences and fails to highlight the broader evolutionary context. Understanding the full range of biological and evolutionary factors that influence the spread and outcomes of infections is critical to formulating effective individual therapies and public health interventions. Therefore, more accurate terminology should be used to refer these multidrug-resistant bacteria.
Pathogens and Immunity abides by Creative Commons BY 4.0:
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
1. McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R, Hinkle M, Whitman T, Lesho E, Schaecher KE. Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: First Report of mcr-1 in the United States. Antimicrob Agents Chemother. 2016;60(7):4420-1. PubMed PMID: 27230792. Pubmed Central PMCID: 4914657. Doi: 10.1128/AAC.01103-16
2. Tavernise, S. and Grady, D. Infection raises the specter of superbugs resistant to all antibiotics. May 26, 2016. http://www.nytimes.com/2016/05/27/health/infection-raises-specter-of-superbugs-resistant-to-all-antibiotics.html?ref=topics. (last accessed on 9/13/16)
3. On Point. Antibiotic resistant superbug arrives in America. http://www.wbur.org/onpoint/2016/05/31/antibiotic-superbug. May 31, 2016. (last accessed on 9/13/16)
4. Emanuel, E. Want to win $2 billion? Create the next antibiotic. Washington Post, May 30, 2016. https://www.washingtonpost.com/opinions/a-super-strategy-for-fighting-superbugs/2016/05/30/38e94370-25a9-11e6-ae4a-3cdd5fe74204_story.html?tid=a_inl&utm_term=.f0de21a95c5d. (last accessed on 9/13/16)
5. Melnyk AH, Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evol Appl. 2015;8(3):273-83. PubMed PMID: 25861385. Pubmed Central PMCID: 4380921. doi: 10.1111/eva.12196
6. Grandjean L, Gilman RH, Martin L, Soto E, Castro B, Lopez S, Coronel J, Castillo E, Alarcon V, Lopez V, San Miguel A, Quispe N, Asencios L, Dye C, Moore DA. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLoS Med. 2015;12(6):e1001843; discussion e. PubMed PMID: 26103620. Pubmed Central PMCID: 4477882. doi: 10.1371/journal.pmed.1001843
7. Baym M, Lieberman TD, Kelsic ED, Chait R, Gross R, Yelin I, Kishony R. Spatiotemporal microbial evolution on antibiotic landscapes. Science. 2016;353(6304):1147-51. PubMed PMID: 27609891. doi: 10.1126/science.aag0822
8. Guillard T, Pons S, Roux D, Pier GB, Skurnik D. Antibiotic resistance and virulence: Understanding the link and its consequences for prophylaxis and therapy. Bioessays. 2016;38(7):682-93. PubMed PMID: 27248008. doi: 10.1002/bies.201500180
9. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15. PubMed PMID: 23323867. doi: 10.1056/NEJMoa120503710. Baym M, Stone LK, Kishony R. Multidrug evolutionary strategies to reverse antibiotic resistance. Science. 2016;351(6268):aad3292. PubMed PMID: 26722002. doi: 10.1126/science.aad3292